These findings have important implications for the utility of B1SP as a cancer therapeutic agent exhibiting broad multi‐RTK inhibiting activity targeting MET, HER2, and EGFR activated by SEMA3C and its cognate ligands. The gene discussed is ERBB2; the disease is cancer.